{"log_id": 1863289788441841063, "direction": 0, "words_result_num": 33, "words_result": [{"probability": {"variance": 0.001944, "average": 0.985562, "min": 0.716227}, "location": {"width": 740, "top": 210, "height": 36, "left": 229}, "words": "文拉法辛主要的代谢酶是CYP2D6和CYP3A4,尚无文拉法辛与同时抑制CYP2D6和"}, {"probability": {"variance": 0.057041, "average": 0.804129, "min": 0.4582}, "location": {"width": 25, "top": 126, "height": 130, "left": 1115}, "words": "一食5附一"}, {"probability": {"variance": 6.3e-05, "average": 0.995604, "min": 0.958512}, "location": {"width": 779, "top": 255, "height": 38, "left": 190}, "words": "CYP3A4酶的药物合用的研究。但可以预见如合用会使文拉法辛血药浓度升高。因此,当文"}, {"probability": {"variance": 0.000301, "average": 0.992048, "min": 0.906845}, "location": {"width": 539, "top": 304, "height": 34, "left": 189}, "words": "拉法辛与这些CYP2D6和CYP3A4双重抑制剂合并使用时需谨慎"}, {"probability": {"variance": 0.000163, "average": 0.990942, "min": 0.954919}, "location": {"width": 263, "top": 352, "height": 32, "left": 190}, "words": "经细胞色素P450酶代谢的药物"}, {"probability": {"variance": 0.001788, "average": 0.985551, "min": 0.730779}, "location": {"width": 736, "top": 391, "height": 36, "left": 234}, "words": "CYP2D6体外研究显示文拉法辛对CYP2D6的抑制作用较弱,这在文拉法辛和氟西汀"}, {"probability": {"variance": 0.01453, "average": 0.963442, "min": 0.363587}, "location": {"width": 584, "top": 438, "height": 36, "left": 192}, "words": "对经CP2D6酶代谢的药物美沙芬代谢影响的对照研究中也得到证实"}, {"probability": {"variance": 0.013096, "average": 0.963794, "min": 0.393084}, "location": {"width": 735, "top": 480, "height": 38, "left": 235}, "words": "丙嗪:文拉法辛对丙咪嗪和2一羟丙咪嗪的药动学没有影响。丙咪嗪不影响文拉法辛"}, {"probability": {"variance": 0.032757, "average": 0.871213, "min": 0.490167}, "location": {"width": 235, "top": 532, "height": 31, "left": 195}, "words": "和ODV的代谢器"}, {"probability": {"variance": 0.00559, "average": 0.972228, "min": 0.623773}, "location": {"width": 738, "top": 569, "height": 41, "left": 234}, "words": "利培酮口服文拉法150mg/天达到稳态时轻度抑制由CYP2D6酶代谢的利培酮(单次"}, {"probability": {"variance": 0.000805, "average": 0.977918, "min": 0.92142}, "location": {"width": 79, "top": 627, "height": 24, "left": 195}, "words": "口服1mg"}, {"probability": {"variance": 0.001563, "average": 0.985314, "min": 0.796326}, "location": {"width": 601, "top": 617, "height": 30, "left": 371}, "words": "性代谢产物9一羟利培酮,导致利培酮的AUC增加约32%。但是合用文"}, {"probability": {"variance": 0.000131, "average": 0.994413, "min": 0.94834}, "location": {"width": 677, "top": 661, "height": 34, "left": 194}, "words": "拉法辛对总体活性部分(利培酮和9一羟利培酮)的药物动力学特征无明显影响"}, {"probability": {"variance": 0.00152, "average": 0.982421, "min": 0.810861}, "location": {"width": 732, "top": 705, "height": 35, "left": 241}, "words": "CYP3A4:在体外文拉法辛不抑制CYP3A4的活性。这在人体的药物相互作用研究中得"}, {"probability": {"variance": 0.003378, "average": 0.985975, "min": 0.641288}, "location": {"width": 685, "top": 750, "height": 35, "left": 194}, "words": "到证实,文拉法辛不抑制阿普唑仑、地西泮和特非那丁等CYP3A4酶底物的代谢"}, {"probability": {"variance": 0.00151, "average": 0.986794, "min": 0.758472}, "location": {"width": 736, "top": 795, "height": 34, "left": 239}, "words": "印地那韦:在9名健康志愿者的研究中,口服文拉法辛150mg天达到稳态时,文拉法辛"}, {"probability": {"variance": 2e-06, "average": 0.998431, "min": 0.995848}, "location": {"width": 114, "top": 850, "height": 23, "left": 197}, "words": "使单次口服8"}, {"probability": {"variance": 0.00318, "average": 0.984803, "min": 0.655172}, "location": {"width": 620, "top": 840, "height": 32, "left": 355}, "words": "的印地那韦的AUC下降28%,使Cmax减低36%。印地那韦不影响文拉法"}, {"probability": {"variance": 0.002851, "average": 0.975351, "min": 0.839757}, "location": {"width": 281, "top": 889, "height": 26, "left": 199}, "words": "辛和ODV的代谢。临床意义不明"}, {"probability": {"variance": 0.001359, "average": 0.984434, "min": 0.800375}, "location": {"width": 719, "top": 927, "height": 36, "left": 240}, "words": " CYPIA2:在体外文拉法辛不抑制CYP1A2。这在人体的药物相互作用研究中得以证实"}, {"probability": {"variance": 0.00071, "average": 0.989378, "min": 0.867638}, "location": {"width": 402, "top": 977, "height": 32, "left": 206}, "words": "文拉法辛不抑制咖啡因(CYP1A2底物)的代谢"}, {"probability": {"variance": 0.006219, "average": 0.968343, "min": 0.556359}, "location": {"width": 743, "top": 1018, "height": 35, "left": 237}, "words": "CYP2C9:在体外文拉法辛不抑制CYP2C9。在体内,口服文拉法辛(75mg,q12h,连"}, {"probability": {"variance": 0.003224, "average": 0.975525, "min": 0.770965}, "location": {"width": 588, "top": 1061, "height": 35, "left": 199}, "words": "服1月)不影响单剂量500mg的甲苯磺丁脲或4一羟甲苯磺丁脲的代谢"}, {"probability": {"variance": 0.002504, "average": 0.981589, "min": 0.695053}, "location": {"width": 676, "top": 1104, "height": 36, "left": 241}, "words": "CYP2C19:文拉法辛不影响主要由CYP2C19代谢的地西泮的代谢(见地西泮)"}, {"probability": {"variance": 0, "average": 0.889282, "min": 0.889282}, "location": {"width": 65, "top": 1163, "height": 18, "left": 201}, "words": " MAOIS"}, {"probability": {"variance": 0.000833, "average": 0.990836, "min": 0.8627}, "location": {"width": 710, "top": 1194, "height": 34, "left": 248}, "words": "如果停用 MAOIS不久后开始文拉法辛治疗,或停用文拉法辛不久就开始 MAOIS治疗"}, {"probability": {"variance": 0.000585, "average": 0.994502, "min": 0.844012}, "location": {"width": 753, "top": 1238, "height": 35, "left": 204}, "words": "有时会发生甚至严重的不良反应。这些不良反应包括震颤、肌痉挛、大汗淋漓、恶心、呕吐"}, {"probability": {"variance": 0.000224, "average": 0.994353, "min": 0.923038}, "location": {"width": 776, "top": 1282, "height": 35, "left": 203}, "words": "潮红、头晕、伴有类似于神经阻滞剂恶性综合征特征的高热、癫痫发作、以至死亡。(见【禁"}, {"probability": {"variance": 0.001144, "average": 0.982614, "min": 0.900275}, "location": {"width": 141, "top": 1335, "height": 25, "left": 202}, "words": "忌】和【警告】"}, {"probability": {"variance": 0.000346, "average": 0.987199, "min": 0.937855}, "location": {"width": 199, "top": 1380, "height": 27, "left": 207}, "words": "中枢神经系统活性药物"}, {"probability": {"variance": 5.7e-05, "average": 0.997212, "min": 0.953975}, "location": {"width": 732, "top": 1416, "height": 35, "left": 248}, "words": "除了上述有关药物外,文拉法辛和其它中枢神经系统活性药物合用的风险缺乏系统地"}, {"probability": {"variance": 2.9e-05, "average": 0.997469, "min": 0.967508}, "location": {"width": 774, "top": 1461, "height": 36, "left": 206}, "words": "评估。因此,当文拉法辛和其它中枢神经系统活性药物合并使用时应慎重。根据文拉法辛的"}, {"probability": {"variance": 0.003371, "average": 0.978417, "min": 0.731482}, "location": {"width": 775, "top": 1506, "height": 33, "left": 205}, "words": "作用机制,本品有可能引起5一HT综合征,应注意文拉法辛和其它作用于5一HT系统的药物"}], "language": 3}